Literature DB >> 35763054

Intracellular Binding of Terfenadine Competes with Its Access to Pancreatic ß-cell ATP-Sensitive K+ Channels and Human ether-à-go-go-Related Gene Channels.

Bernd J Zünkler1,2, Maria Wos-Maganga3, Stefanie Bohnet3, Anne Kleinau3, Detlef Manns3, Shivani Chatterjee3.   

Abstract

Most blockers of both hERG (human ether-à-go-go-related gene) channels and pancreatic ß-cell ATP-sensitive K+ (KATP) channels access their binding sites from the cytoplasmic side of the plasma membrane. It is unknown whether binding to intracellular components competes with binding of these substances to K+ channels. The whole-cell configuration of the patch-clamp technique, a laser-scanning confocal microscope, and fluorescence correlation spectroscopy (FCS) were used to study hERG channels expressed in HEK (human embryonic kidney) 293 cells and KATP channels from the clonal insulinoma cell line RINm5F. When applied via the pipette solution in the whole-cell configuration, terfenadine blocked both hERG and KATP currents with much lower potency than after application via the bath solution, which was not due to P-glycoprotein-mediated efflux of terfenadine. Such a difference was not observed with dofetilide and tolbutamide. 37-68% of hERG/EGFP (enhanced green-fluorescent protein) fusion proteins expressed in HEK 293 cells were slowly diffusible as determined by laser-scanning microscopy in the whole-cell configuration and by FCS in intact cells. Bath application of a green-fluorescent sulphonylurea derivative (Bodipy-glibenclamide) induced a diffuse fluorescence in the cytosol of RINm5F cells under whole-cell patch-clamp conditions. These observations demonstrate the presence of intracellular binding sites for hERG and KATP channel blockers not dialyzable by the patch-pipette solution. Intracellular binding of terfenadine was not influenced by a mutated hERG (Y652A) channel. In conclusion, substances with high lipophilicity are not freely diffusible inside the cell but steep concentration gradients might exist within the cell and in the sub-membrane space.
© 2022. The Author(s).

Entities:  

Keywords:  Intracellular binding; KATP channel; Terfenadine; hERG channel

Year:  2022        PMID: 35763054     DOI: 10.1007/s00232-022-00252-y

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  36 in total

Review 1.  Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Authors:  I Cavero; M Mestre; J M Guillon; E Heuillet; A G Roach
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

Authors:  M H Bridgland-Taylor; A C Hargreaves; A Easter; A Orme; D C Henthorn; M Ding; A M Davis; B G Small; C G Heapy; N Abi-Gerges; F Persson; I Jacobson; M Sullivan; N Albertson; T G Hammond; E Sullivan; J-P Valentin; C E Pollard
Journal:  J Pharmacol Toxicol Methods       Date:  2006-03-06       Impact factor: 1.950

3.  In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.

Authors:  Sonia Goineau; Jean-Laurent Lacaud; Christophe Legrand; Emilie Eveilleaux; Vincent Castagné
Journal:  Regul Toxicol Pharmacol       Date:  2013-10-09       Impact factor: 3.271

4.  Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.

Authors:  C Y DU; A El Harchi; Y H Zhang; C H Orchard; J C Hancox
Journal:  J Cardiovasc Electrophysiol       Date:  2011-04-13

5.  Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.

Authors:  Nina Brinkwirth; Kiyoshi Takasuna; Masafumi Doi; Nadine Becker; Alison Obergrussberger; Søren Friis; Hatsue Furukawa; Yuka Hasegawa; Takayuki Oka; Atsushi Ohtsuki; Niels Fertig; Sonja Stoelzle-Feix
Journal:  J Pharmacol Toxicol Methods       Date:  2020-06-18       Impact factor: 1.950

6.  P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model.

Authors:  Claude Dagenais; Alex Avdeef; Oksana Tsinman; Adam Dudley; Richard Beliveau
Journal:  Eur J Pharm Sci       Date:  2009-07-08       Impact factor: 4.384

7.  Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Robert Cox; Mark A Demitrack; Michael J Fossler; Michael Kramer; Robert B Kleiman; Peter Kowey; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2021-09-02       Impact factor: 6.343

8.  Interactions at human ether-à-go-go-related gene channels.

Authors:  Anne Friemel; Bernd J Zünkler
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

9.  Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins.

Authors:  Sonja Claassen; Sarah Schwarzer; Jost Ludwig; Bernd J Zünkler
Journal:  J Membr Biol       Date:  2008-03       Impact factor: 1.843

Review 10.  An Update on the Structure of hERG.

Authors:  Andrew Butler; Matthew V Helliwell; Yihong Zhang; Jules C Hancox; Christopher E Dempsey
Journal:  Front Pharmacol       Date:  2020-01-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.